Mirum Pharmaceuticals (MIRM)

Executive Summary

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare cholestatic liver diseases. Its lead product, LIVMARLI (maralixibat), is FDA-approved for the treatment of cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). The company has established a commercial footprint and is expanding its pipeline to address additional indications, including biliary atresia and intrahepatic cholestasis of pregnancy. With a strong position in the rare liver disease space and a growing portfolio, Mirum is poised for continued growth through label expansions and geographic expansion. The company's focus on high unmet medical needs and orphan drug designations provides a competitive advantage, though commercial uptake remains dependent on patient identification and reimbursement.

Upcoming Catalysts (preview)

• Q4 2026EMA Decision on LIVMARLI for PFIC75% success
• Q3 2026Phase 2 Biliary Atresia Data Presentation80% success
• H1 2027LIVMARLI Label Expansion for Pediatric PFIC Subtypes65% success